catalyx space | $5,400,000 | (Nov 4, 2025)
Indomo | $25,000,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
Rapport Therapeutics
United States
- Boston, Massachusetts
- 08/03/2023
- Series A
- $100,000,000
Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.
- Industry Biotechnology Research
- Website https://www.rapportrx.com/
- LinkedIn https://www.linkedin.com/company/rapport-therapeutics/
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
Popai Health | $11,000,000 | (Nov 4, 2025)
Helex | $3,500,000 | (Nov 4, 2025)
AUI™ (Augmented Intelligence) | $20,000,000 | (Nov 4, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)